See more : CC Japan Income & Growth Trust plc (CCJS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Teleflex Incorporated (TFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teleflex Incorporated, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Games & Esports Experience Acquisition Corp. (GEEXU) Income Statement Analysis – Financial Results
- Aeroports de Paris SA (ARRPY) Income Statement Analysis – Financial Results
- Comtec Systems Co.,Ltd. (031820.KS) Income Statement Analysis – Financial Results
- Global Consumer Acquisition Corp. (GACQW) Income Statement Analysis – Financial Results
- Commercial National Financial Corporation (CNAF) Income Statement Analysis – Financial Results
Teleflex Incorporated (TFX)
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.97B | 2.79B | 2.81B | 2.54B | 2.60B | 2.45B | 2.15B | 1.87B | 1.81B | 1.84B | 1.70B | 1.55B | 1.53B | 1.80B | 1.89B | 2.42B | 1.93B | 2.65B | 2.51B | 2.49B | 2.28B | 2.08B | 1.91B | 1.76B | 1.60B | 1.44B | 1.15B | 931.20M | 912.70M | 812.70M | 666.80M | 567.10M | 479.50M | 441.10M | 355.60M | 328.20M | 269.80M | 214.20M | 171.80M |
| Cost of Revenue | 1.33B | 1.26B | 1.26B | 1.21B | 1.10B | 1.06B | 974.50M | 871.83M | 865.29M | 897.40M | 857.33M | 802.78M | 810.07M | 1.01B | 1.08B | 1.46B | 1.25B | 1.87B | 1.80B | 1.79B | 1.68B | 1.52B | 1.37B | 1.20B | 1.09B | 969.60M | 746.90M | 601.40M | 590.30M | 524.40M | 431.00M | 360.40M | 311.80M | 286.90M | 237.20M | 215.50M | 175.80M | 140.50M | 114.70M |
| Gross Profit | 1.65B | 1.53B | 1.55B | 1.32B | 1.49B | 1.38B | 1.17B | 996.20M | 944.40M | 942.43M | 838.95M | 748.23M | 718.84M | 794.07M | 814.08M | 964.17M | 680.35M | 774.19M | 709.95M | 698.80M | 597.79M | 552.45M | 535.29M | 567.70M | 512.60M | 468.00M | 398.90M | 329.80M | 322.40M | 288.30M | 235.80M | 206.70M | 167.70M | 154.20M | 118.40M | 112.70M | 94.00M | 73.70M | 57.10M |
| Gross Profit Ratio | 55.37% | 54.86% | 55.15% | 52.22% | 57.47% | 56.55% | 54.60% | 53.33% | 52.19% | 51.22% | 49.46% | 48.24% | 47.02% | 44.07% | 43.07% | 39.83% | 35.17% | 29.25% | 28.23% | 28.12% | 26.19% | 26.61% | 28.10% | 32.17% | 32.02% | 32.55% | 34.81% | 35.42% | 35.32% | 35.47% | 35.36% | 36.45% | 34.97% | 34.96% | 33.30% | 34.34% | 34.84% | 34.41% | 33.24% |
| Research & Development | 154.35M | 153.82M | 130.84M | 119.75M | 113.86M | 106.21M | 84.77M | 58.58M | 52.12M | 61.04M | 65.05M | 56.28M | 48.73M | 42.62M | 0.00 | 0.00 | 30.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 991.05M | 863.75M | 860.09M | 743.57M | 934.37M | 878.69M | 699.96M | 563.31M | 568.98M | 578.66M | 502.19M | 454.49M | 429.26M | 475.32M | 519.93M | 596.77M | 445.25M | 493.52M | 449.04M | 494.43M | 423.03M | 365.02M | 347.13M | 311.28M | 284.70M | 266.10M | 230.20M | 190.30M | 192.40M | 173.90M | 141.00M | 124.20M | 93.70M | 84.80M | 63.90M | 59.10M | 49.60M | 39.80M | 31.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 582.00K | -341.00K | 2.60M | 2.34M | 0.00 | 838.00K | -14.22M | -2.73M | -1.93B | -18.90M | 0.00 | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| Operating Expenses | 1.14B | 1.02B | 990.93M | 863.32M | 1.05B | 984.90M | 784.73M | 621.89M | 621.10M | 639.70M | 567.23M | 510.77M | 478.58M | 517.60M | 522.52M | 624.18M | 445.25M | 494.35M | 434.82M | 491.70M | -1.51B | 346.12M | 347.13M | 388.70M | 352.10M | 326.20M | 278.10M | 229.10M | 230.10M | 206.90M | 169.10M | 145.80M | 112.10M | 102.00M | 76.80M | 70.10M | 59.40M | 47.00M | 36.50M |
| Cost & Expenses | 2.47B | 2.28B | 2.25B | 2.08B | 2.15B | 2.05B | 1.76B | 1.49B | 1.49B | 1.54B | 1.42B | 1.31B | 1.29B | 1.53B | 1.60B | 2.08B | 1.70B | 2.37B | 2.24B | 2.28B | 177.83M | 1.87B | 1.72B | 1.59B | 1.44B | 1.30B | 1.03B | 830.50M | 820.40M | 731.30M | 600.10M | 506.20M | 423.90M | 388.90M | 314.00M | 285.60M | 235.20M | 187.50M | 151.20M |
| Interest Income | 12.78M | 912.00K | 1.33M | 1.16M | 1.74M | 944.00K | 771.00K | 474.00K | 532.00K | 706.00K | 624.00K | 1.57M | 1.26M | 861.00K | 2.54M | 2.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 85.08M | 54.26M | 56.97M | 66.49M | 80.27M | 103.02M | 82.55M | 54.94M | 61.32M | 65.46M | 56.91M | 69.57M | 70.32M | 80.03M | 89.46M | 121.65M | 0.00 | 0.00 | 0.00 | 37.12M | 26.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.12M | 230.59M | 237.36M | 227.25M | 214.06M | 209.98M | 155.26M | 117.91M | 108.39M | 111.13M | 92.98M | 80.47M | 85.62M | 92.19M | 101.06M | 111.22M | 78.76M | 99.00M | 100.85M | 114.60M | 104.35M | 95.12M | 92.40M | 77.42M | 67.40M | 60.10M | 47.90M | 38.80M | 37.70M | 33.00M | 28.10M | 21.60M | 18.40M | 17.20M | 12.90M | 11.00M | 9.80M | 7.20M | 4.80M |
| EBITDA | 761.21M | 751.65M | 873.10M | 665.98M | 634.24M | 532.63M | 522.72M | 418.57M | 414.36M | 396.70M | 325.61M | -26.39M | 288.87M | 302.71M | 353.78M | 453.84M | 313.86M | 309.20M | 284.14M | 308.41M | 302.80M | 307.27M | 280.56M | 256.42M | 227.90M | 201.90M | 168.70M | 139.50M | 130.00M | 114.40M | 94.80M | 82.50M | 74.00M | 69.40M | 54.50M | 53.60M | 44.40M | 33.90M | 25.40M |
| EBITDA Ratio | 25.59% | 26.69% | 28.38% | 27.19% | 25.40% | 24.93% | 25.30% | 26.38% | 23.88% | 22.53% | 21.54% | 20.60% | 15.80% | 20.51% | 20.91% | 18.75% | 19.40% | 15.30% | 15.46% | 15.55% | 96.65% | 14.03% | 14.73% | 14.53% | 14.23% | 14.04% | 14.72% | 14.98% | 14.24% | 14.08% | 14.22% | 13.98% | 14.70% | 15.03% | 14.09% | 16.33% | 15.72% | 13.96% | 12.92% |
| Operating Income | 506.31M | 499.73M | 628.10M | 423.07M | 427.25M | 321.70M | 372.28M | 319.45M | 315.89M | 284.86M | 233.26M | -97.38M | 233.17M | 273.59M | 269.77M | 339.99M | 192.64M | 254.61M | 248.07M | 139.49M | 2.10B | 206.33M | 188.16M | 179.00M | 160.50M | 141.80M | 120.80M | 100.70M | 92.30M | 81.40M | 66.70M | 60.90M | 55.60M | 52.20M | 41.60M | 42.60M | 34.60M | 26.70M | 20.60M |
| Operating Income Ratio | 17.02% | 17.90% | 22.36% | 16.67% | 16.46% | 13.14% | 17.35% | 17.10% | 17.46% | 15.48% | 13.75% | -6.28% | 15.25% | 15.19% | 14.27% | 14.04% | 9.96% | 9.62% | 9.87% | 5.61% | 92.21% | 9.94% | 9.88% | 10.14% | 10.02% | 9.86% | 10.54% | 10.81% | 10.11% | 10.02% | 10.00% | 10.74% | 11.60% | 11.83% | 11.70% | 12.98% | 12.82% | 12.46% | 11.99% |
| Total Other Income/Expenses | -72.30M | -53.81M | -68.63M | -65.34M | -122.08M | 23.20M | -87.37M | -73.73M | -71.25M | -64.75M | -57.53M | -181.78M | -84.47M | -82.50M | -86.92M | -119.01M | -83.29M | -35.93M | -39.67M | -42.35M | -23.27M | -33.84M | -28.47M | -20.79M | -17.77M | -16.98M | -14.40M | -13.90M | -18.70M | -18.40M | -14.40M | -12.30M | -10.30M | -9.30M | -2.40M | -6.20M | -2.90M | 200.00K | 1.60M |
| Income Before Tax | 434.01M | 445.92M | 559.47M | 357.73M | 339.90M | 219.63M | 284.91M | 245.73M | 244.65M | 220.11M | 175.73M | -165.37M | 148.70M | 147.79M | 182.85M | 220.98M | 109.35M | 219.03M | 207.92M | 102.37M | 151.49M | 172.49M | 159.70M | 158.21M | 142.70M | 124.80M | 106.40M | 86.80M | 73.60M | 63.00M | 52.30M | 48.60M | 45.30M | 42.90M | 39.20M | 36.40M | 31.70M | 26.90M | 22.20M |
| Income Before Tax Ratio | 14.59% | 15.98% | 19.91% | 14.10% | 13.10% | 8.97% | 13.27% | 13.15% | 13.52% | 11.96% | 10.36% | -10.66% | 9.73% | 8.20% | 9.67% | 9.13% | 5.65% | 8.28% | 8.27% | 4.12% | 6.64% | 8.31% | 8.38% | 8.97% | 8.91% | 8.68% | 9.29% | 9.32% | 8.06% | 7.75% | 7.84% | 8.57% | 9.45% | 9.73% | 11.02% | 11.09% | 11.75% | 12.56% | 12.92% |
| Income Tax Expense | 76.44M | 83.00M | 74.35M | 21.93M | -122.08M | 23.20M | 129.65M | 8.07M | 7.84M | 28.65M | 23.55M | 16.41M | 27.00M | 21.89M | 39.90M | 52.17M | 122.77M | 54.14M | 47.81M | 14.35M | 42.39M | 47.22M | 47.38M | 48.99M | 47.50M | 42.20M | 36.30M | 29.60M | 24.70M | 21.80M | 18.60M | 16.60M | 15.50M | 14.30M | 12.40M | 12.40M | 12.00M | 10.50M | 8.90M |
| Net Income | 356.33M | 363.14M | 485.37M | 335.32M | 461.47M | 200.80M | 152.53M | 237.38M | 244.86M | 187.68M | 150.88M | -190.06M | 323.33M | 201.09M | 302.99M | 119.77M | 146.48M | 139.43M | 138.82M | 9.52M | 109.10M | 125.27M | 112.31M | 109.22M | 95.20M | 82.60M | 70.10M | 57.20M | 48.90M | 41.20M | 33.70M | 32.90M | 29.80M | 28.60M | 26.80M | 24.00M | 19.70M | 16.40M | 13.30M |
| Net Income Ratio | 11.98% | 13.01% | 17.28% | 13.22% | 17.78% | 8.20% | 7.11% | 12.71% | 13.53% | 10.20% | 8.89% | -12.25% | 21.15% | 11.16% | 16.03% | 4.95% | 7.57% | 5.27% | 5.52% | 0.38% | 4.78% | 6.03% | 5.90% | 6.19% | 5.95% | 5.75% | 6.12% | 6.14% | 5.36% | 5.07% | 5.05% | 5.80% | 6.21% | 6.48% | 7.54% | 7.31% | 7.30% | 7.66% | 7.74% |
| EPS | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 | 5.89 | 4.54 | 3.67 | -4.65 | 7.98 | 5.04 | 7.63 | 3.03 | 3.73 | 3.51 | 3.43 | 0.24 | 2.76 | 3.12 | 2.90 | 2.86 | 2.52 | 2.21 | 1.91 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| EPS Diluted | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 | 5.10 | 4.04 | 3.45 | -4.65 | 7.92 | 4.99 | 7.59 | 3.01 | 3.73 | 3.49 | 3.39 | 0.24 | 2.73 | 3.08 | 2.86 | 2.83 | 2.47 | 2.15 | 1.86 | 1.58 | 1.38 | 1.18 | 0.98 | 0.97 | 0.89 | 0.87 | 0.82 | 0.74 | 0.60 | 0.51 | 0.42 |
| Weighted Avg Shares Out | 46.98M | 46.90M | 46.77M | 46.49M | 46.20M | 45.69M | 45.00M | 43.33M | 41.56M | 41.37M | 41.11M | 40.86M | 40.50M | 39.91M | 39.72M | 39.58M | 39.26M | 39.76M | 40.52M | 40.21M | 39.60M | 40.15M | 38.73M | 38.19M | 37.78M | 37.38M | 36.70M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
| Weighted Avg Shares Out (Dil) | 47.30M | 47.31M | 47.43M | 47.29M | 47.09M | 46.80M | 46.66M | 47.65M | 48.06M | 46.47M | 43.69M | 40.86M | 40.80M | 40.28M | 39.94M | 39.83M | 39.26M | 39.99M | 40.96M | 40.50M | 39.94M | 40.67M | 39.27M | 38.60M | 38.54M | 38.42M | 37.69M | 36.20M | 35.56M | 35.06M | 34.39M | 33.92M | 33.48M | 32.87M | 32.68M | 32.43M | 32.83M | 32.16M | 31.67M |
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
Teleflex (TFX) came out with quarterly earnings of $3.38 per share, beating the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.52 per share a year ago.
Teleflex beats quarterly profit estimates on strong demand for medical devices
Teleflex reported fourth-quarter profit above Wall Street estimates on Thursday, on the back of strong demand for its medical devices and surgical equipment.
Teleflex Announces Quarterly Dividend
WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 15, 2024,...
Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results
WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summary Revenues of $773.9 million , reflective of five fewer shipping days year-over-year,...
Teleflex to Present at the 45th Annual Raymond James Institutional Investors Conference
WAYNE, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 45th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL,...
Countdown to Teleflex (TFX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Teleflex (TFX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex Announces Fourth Quarter 2023 Earnings Conference Call Information
WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 22, 2024.
3 Top Stock Picks from America's Leading SMID-Cap Fund
There are small-cap funds, and there are mid-cap funds, and those invest in both. These are what you call SMID-Cap funds.
Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
A New Choice for Bariatric Surgeons: Titan SGS ™ Standard Staple Line Reinforcement with GORE ® SEAMGUARD ® Bioabsorbable Staple Line Reinforcement
Source: https://incomestatements.info
Category: Stock Reports